| Budget Amount *help |
¥17,290,000 (Direct Cost: ¥13,300,000、Indirect Cost: ¥3,990,000)
Fiscal Year 2019: ¥3,380,000 (Direct Cost: ¥2,600,000、Indirect Cost: ¥780,000)
Fiscal Year 2018: ¥3,380,000 (Direct Cost: ¥2,600,000、Indirect Cost: ¥780,000)
Fiscal Year 2017: ¥4,810,000 (Direct Cost: ¥3,700,000、Indirect Cost: ¥1,110,000)
Fiscal Year 2016: ¥5,720,000 (Direct Cost: ¥4,400,000、Indirect Cost: ¥1,320,000)
|
|---|
| Outline of Final Research Achievements |
In this study, we aimed to delineate the full O-Man glycan structure of a-dystroglycan (a-DG) whose abnormalities cause muscular dystrophy, to clarify the biosynthesis pathway of the glycan, to understand the pathogenesis of neuronal dysfunction of the disease, and to explore its therapeutic possibility. We determined the unknown glycan structure that contained ribitol phosphate. We also identified the functions of four gene proteins such as fukutin that are responsible for muscular dystrophy, and determined the biosynthesis pathway for ribitol phosphate of the glycan. We could not find novel proteins modified with the O-Man glycan or a-DG ligands. Some therapeutic strategies were found to be effective for the disease model cells and mice. Further investigations are required.
|
